Foley Hoag Represents Alloy Therapeutics in Strategic Collaboration With Takeda
December 04, 2024
December 04, 2024
BOSTON, Massachusetts, Dec. 4 -- Foley Hoag, a law firm, issued the following news:
Foley Hoag LLP represented biotechnology ecosystem company Alloy Therapeutics Inc. ("Alloy") in a strategic collaboration and license agreement with Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") for the development of Takeda's proprietary induced pluripotent stem cell (iPSC) derived CAR-T cell platform (iCAR-T) and iPSC-derived CAR-NK platform (iCAR-NK).
Foley Hoag LLP represented biotechnology ecosystem company Alloy Therapeutics Inc. ("Alloy") in a strategic collaboration and license agreement with Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") for the development of Takeda's proprietary induced pluripotent stem cell (iPSC) derived CAR-T cell platform (iCAR-T) and iPSC-derived CAR-NK platform (iCAR-NK).